Obesity drugmakers Orexigen, Vivus continue to falter

Bad news for struggling obesity drugmakers: Things aren't going to get any better, one analyst says. And the way he sees it, for leaders Orexigen ($OREX) and Vivus ($VVUS), they're likely to get much worse. More from FiercePharmaMarketing

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.